Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
← catalyst calendarNCT03836482 · readout ≤ 193 d
Sponsored by SeaStar Medical (industry) · ICU — their whole pipeline →. With National Heart, Lung, and Blood Institute (NHLBI), University of Michigan, Innovative BioTherapies (IBT).
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-02 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute on Chronic Systolic Congestive Heart Failure
- Cardiorenal Syndrome
Intervention
- Device: Selective Cytopheretic Device
Primary outcomes
what the primary-completion date above is the date OFNeed for continuous IV vasopressor support
measured measured daily, at or after 4 hours after termination of daily SCD therapy
Acute myocardial infarction
measured up to 6 months following SCD treatment initiation
Mortality
measured up to 6 months following SCD treatment initiation
Percentage of subjects with reversal of WRF and increase eGFR and PCW
measured up to 6 days after initiation of SCD therapy
Percentage of subjects who no longer have severe right ventricular failure
measured up to 6 days after initiation of SCD therapy
Adverse Events
measured up to 6 days after initiation of SCD therapy
Permalink · ICU's whole pipeline · Catalyst calendar · Every registered study · What changed